In the study, we discuss below the differences in the expression of SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP in primary GBM IDH-wild-type female cells (GBM5-1F, GBM5-2F, and GBM5-3F), and the differences in the response of the tested cells to the effects of the treatment with NaVPA–NaDCA compared to the impact of the treatment with TMZ. The gene discussed is SLC12A2; the disease is glioblastoma.